Published in Cancer Gene Ther on November 09, 2012
Trial Watch:: Oncolytic viruses for cancer therapy. Oncoimmunology (2014) 1.22
New insights into IL-12-mediated tumor suppression. Cell Death Differ (2014) 1.09
Trial Watch-Oncolytic viruses and cancer therapy. Oncoimmunology (2015) 0.83
Microtubule disruption synergizes with oncolytic virotherapy by inhibiting interferon translation and potentiating bystander killing. Nat Commun (2015) 0.82
Novel delivery approaches for cancer therapeutics. J Control Release (2015) 0.79
Unlocking the promise of oncolytic virotherapy in glioma: combination with chemotherapy to enhance efficacy. Ther Deliv (2015) 0.78
Oncolytic virotherapy for urological cancers. Nat Rev Urol (2016) 0.76
Efficient expression of bioactive murine IL12 as a self-processing P2A polypeptide driven by inflammation-regulated promoters in tumor cell lines. Cancer Gene Ther (2015) 0.75
Oncolytic herpes viruses, chemotherapeutics, and other cancer drugs. Oncolytic Virother (2013) 0.75
Targeting tumor vasculature through oncolytic virotherapy: recent advances. Oncolytic Virother (2015) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul (1984) 35.22
Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov (2007) 11.46
Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol (1993) 6.55
Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest (2000) 5.52
Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg (1972) 4.37
Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol (2012) 3.73
Axonal transport of herpes simplex virions to epidermal cells: evidence for a specialized mode of virus transport and assembly. Proc Natl Acad Sci U S A (1994) 3.56
Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst (1995) 3.53
Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med (1995) 3.37
Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science (1991) 3.14
Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev (2002) 2.86
Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches. Cancer Metastasis Rev (2001) 2.16
In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents. J Infect Dis (1988) 1.92
Redistribution of microtubules and Golgi apparatus in herpes simplex virus-infected cells and their role in viral exocytosis. J Virol (1995) 1.86
Antivascular actions of microtubule-binding drugs. Clin Cancer Res (2009) 1.68
Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther (2002) 1.51
Direct in vitro evidence and in vivo analysis of the antiangiogenesis effects of interleukin 12. Cancer Res (2000) 1.30
Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel. Cancer Res (2001) 1.24
Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer. BMC Cancer (2011) 1.17
Microtubule reorganization during herpes simplex virus type 1 infection facilitates the nuclear localization of VP22, a major virion tegument protein. J Virol (2001) 1.17
Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12. Blood (1999) 1.15
Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers. Cancer Gene Ther (2006) 1.11
Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma. Hum Gene Ther (2001) 1.10
Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy. Mol Ther (2006) 1.09
Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors. Clin Cancer Res (2006) 1.09
Angiogenesis inhibition by an oncolytic herpes virus expressing interleukin 12. Clin Cancer Res (2004) 1.08
Bevacizumab with angiostatin-armed oHSV increases antiangiogenesis and decreases bevacizumab-induced invasion in U87 glioma. Mol Ther (2011) 1.04
Oncolytic HSV-1 virotherapy: clinical experience and opportunities for progress. Curr Pharm Biotechnol (2012) 1.03
Synergistic anti-tumor effects between oncolytic vaccinia virus and paclitaxel are mediated by the IFN response and HMGB1. Gene Ther (2010) 1.03
IL-12 regulates an endothelial cell-lymphocyte network: effect on metalloproteinase-9 production. J Immunol (2003) 1.02
Oncolytic herpes simplex virus vectors and taxanes synergize to promote killing of prostate cancer cells. Cancer Gene Ther (2009) 1.01
Tumour targeting by microtubule-depolymerizing vascular disrupting agents. Expert Opin Ther Targets (2007) 1.01
Systemic therapy of spontaneous prostate cancer in transgenic mice with oncolytic herpes simplex viruses. Cancer Res (2007) 0.97
Role of microvessel density in predicting recurrence in pathologic Stage T3 prostatic adenocarcinoma. Urology (1999) 0.95
Oncolytic herpes simplex virus vector therapy of breast cancer in C3(1)/SV40 T-antigen transgenic mice. Cancer Res (2005) 0.93
Systemic oncolytic herpes virus therapy of poorly immunogenic prostate cancer metastatic to lung. Clin Cancer Res (2006) 0.92
Viral oncolysis by herpes simplex virus and other viruses. Cancer Biol Ther (2005) 0.92
Synergy of a herpes oncolytic virus and paclitaxel for anaplastic thyroid cancer. Clin Cancer Res (2008) 0.91
Improved potency and selectivity of an oncolytic E1ACR2 and E1B19K deleted adenoviral mutant in prostate and pancreatic cancers. Clin Cancer Res (2010) 0.90
Efficacy of oncolytic mutants targeting pRb and p53 pathways is synergistically enhanced when combined with cytotoxic drugs in prostate cancer cells and tumor xenografts. Hum Gene Ther (2010) 0.84
Analysis of genetically engineered oncolytic herpes simplex viruses in human prostate cancer organotypic cultures. Gene Ther (2009) 0.81
Transcription profiling-based identification of Staphylococcus aureus genes regulated by the agr and/or sarA loci. J Bacteriol (2001) 5.57
A statistical method for flagging weak spots improves normalization and ratio estimates in microarrays. Physiol Genomics (2001) 4.50
Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther (2000) 4.33
Stress: a factor to be considered in heterotrophic microorganism enumeration from aquatic environments. Appl Microbiol (1974) 4.03
Meningioma: analysis of recurrence and progression following neurosurgical resection. J Neurosurg (1985) 3.73
Loss of genes on chromosome 22 in tumorigenesis of human acoustic neuroma. Nature (1986) 3.40
Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med (1995) 3.37
Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein. Proc Natl Acad Sci U S A (2000) 2.96
Three-dimensional structure of the alkaline protease of Pseudomonas aeruginosa: a two-domain protein with a calcium binding parallel beta roll motif. EMBO J (1993) 2.80
Sites of termination of in vitro DNA synthesis on ultraviolet- and N-acetylaminofluorene-treated phi X174 templates by prokaryotic and eukaryotic DNA polymerases. Proc Natl Acad Sci U S A (1981) 2.66
Replication-selective virotherapy for cancer: Biological principles, risk management and future directions. Nat Med (2001) 2.64
Ser-His-Glu triad forms the catalytic site of the lipase from Geotrichum candidum. Nature (1991) 2.57
Predicting progression to AIDS: combined usefulness of CD4 lymphocyte counts and p24 antigenemia. Am J Med (1990) 2.56
Genetic linkage of bilateral acoustic neurofibromatosis to a DNA marker on chromosome 22. Nature (1987) 2.32
Intracellular signalling: PDK1--a kinase at the hub of things. Curr Biol (1999) 2.31
Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer's disease. J Clin Invest (1999) 2.21
Common pathogenetic mechanism for three tumor types in bilateral acoustic neurofibromatosis. Science (1987) 2.06
Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor. Science (2000) 2.01
Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci U S A (2001) 1.99
LY341495 is a nanomolar potent and selective antagonist of group II metabotropic glutamate receptors. Neuropharmacology (1998) 1.98
Integrin and cadherin synergy regulates contact inhibition of migration and motile activity. J Cell Biol (1998) 1.91
Detection of herpes simplex viral DNA in the iridocorneal endothelial syndrome. Arch Ophthalmol (1994) 1.88
Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity. Hum Gene Ther (1999) 1.84
Antibody to caspase-cleaved actin detects apoptosis in differentiated neuroblastoma and plaque-associated neurons and microglia in Alzheimer's disease. Am J Pathol (1998) 1.67
Phospholipase D1: a key factor for the exocytotic machinery in neuroendocrine cells. EMBO J (2001) 1.67
In vitro bypass of UV-induced lesions by Escherichia coli DNA polymerase I: specificity of nucleotide incorporation. Proc Natl Acad Sci U S A (1983) 1.64
Molecular genetic approach to human meningioma: loss of genes on chromosome 22. Proc Natl Acad Sci U S A (1987) 1.63
Cell-specific signal transduction of parathyroid hormone (PTH)-related protein through stably expressed recombinant PTH/PTHrP receptors in vascular smooth muscle cells. Endocrinology (1996) 1.61
Glial fibrillary acidic protein-apolipoprotein E (apoE) transgenic mice: astrocyte-specific expression and differing biological effects of astrocyte-secreted apoE3 and apoE4 lipoproteins. J Neurosci (1998) 1.61
Cloning and characterization of the Bacteroides fragilis metalloprotease toxin gene. Infect Immun (1997) 1.58
Activation of a cell-cycle-regulated histone gene by the oncogenic transcription factor IRF-2. Nature (1995) 1.54
Congenital neuromuscular disease with uniform type 1 fiber and RYR1 mutation. Neurology (2007) 1.53
Stigmatization and shame: consequences of caring for HIV/AIDS patients in China. AIDS Care (2007) 1.53
Natural CD8+CD122+ T cells are more potent in suppression of allograft rejection than CD4+CD25+ regulatory T cells. Am J Transplant (2013) 1.52
Strong constraints on the rare decays B(s)(0) → μ+ μ- and B0 → μ+ μ-. Phys Rev Lett (2012) 1.50
A stereoselective cobalt-containing nitrile hydratase. Biochemistry (1997) 1.46
Massive reduction in methicillin resistance by transposon inactivation of the normal PBP2 in a methicillin-resistant strain of Staphylococcus aureus. Microb Drug Resist (1997) 1.45
Chemokine coreceptor usage by diverse primary isolates of human immunodeficiency virus type 1. J Virol (1998) 1.44
Cingulotomy for refractory obsessive-compulsive disorder. A long-term follow-up of 33 patients. Arch Gen Psychiatry (1991) 1.44
Coronary artery fistulae. Am J Med Sci (2006) 1.44
Act locally, think globally. Nat Med (1997) 1.43
Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus. Hum Gene Ther (1999) 1.43
Determination of the X(3872) meson quantum numbers. Phys Rev Lett (2013) 1.42
Assessing prostate cancer growth with citrate measured by intact tissue proton magnetic resonance spectroscopy. Prostate Cancer Prostatic Dis (2012) 1.42
Contribution of endogenously expressed Trp1 to a Ca2+-selective, store-operated Ca2+ entry pathway. FASEB J (2001) 1.41
The X-ray crystal structure of the Trichoderma reesei family 12 endoglucanase 3, Cel12A, at 1.9 A resolution. J Mol Biol (2001) 1.41
Unconventional gap state of trapped exciton in lead sulfide quantum dots. Nanotechnology (2010) 1.41
Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res (1994) 1.41
Effect of acetylated and deacetylated 2-aminofluorene adducts on in vitro DNA synthesis. Proc Natl Acad Sci U S A (1982) 1.40
High frequency of p16INK4A gene alterations in hepatocellular carcinoma. Oncogene (1999) 1.40
Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir. Neurosurgery (1993) 1.39
p55CDC/hCDC20 is associated with BUBR1 and may be a downstream target of the spindle checkpoint kinase. Oncogene (2000) 1.39
Attenuation of esophageal shortening during peristalsis with hiatus hernia. Gastroenterology (1995) 1.39
Quantitative changes in integrin and focal adhesion signaling regulate myoblast cell cycle withdrawal. J Cell Biol (1999) 1.38
Allergy and risk of glioma: a meta-analysis. Eur J Neurol (2010) 1.38
Admixture and population stratification in African Caribbean populations. Ann Hum Genet (2006) 1.37
Optimized expression of green fluorescent protein in Toxoplasma gondii using thermostable green fluorescent protein mutants. Mol Biochem Parasitol (2001) 1.35
Bilateral acoustic neuromas: clinical aspects, pathogenesis, and treatment. Neurosurgery (1982) 1.34
AFM imaging of bacteria in liquid media immobilized on gelatin coated mica surfaces. Ultramicroscopy (2003) 1.31
Expression of recombinant enterotoxigenic Escherichia coli colonization factor antigen I by Salmonella typhimurium elicits a biphasic T helper cell response. Infect Immun (1999) 1.30
Association of epidermal growth factor receptor gene amplification with loss of chromosome 10 in human glioblastoma multiforme. J Neurosurg (1992) 1.28
Direct measurement of human-cone-photoreceptor alignment. J Opt Soc Am A Opt Image Sci Vis (1995) 1.28
Termination of vitro DNA synthesis at AAF adducts in the DNA. Nucleic Acids Res (1980) 1.27
A role for DNA polymerase in the specificity of nucleotide incorporation opposite N-acetyl-2-aminofluorene adducts. J Mol Biol (1984) 1.27
Molecular evolution of the pathogenicity island of enterotoxigenic Bacteroides fragilis strains. J Bacteriol (1999) 1.26
Reduced levels of human apoE4 protein in an animal model of cognitive impairment. Neurobiol Aging (2009) 1.26
Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation of intracerebral injection in nonhuman primates. J Virol (1999) 1.26
Benign spinal nerve sheath tumors: their occurrence sporadically and in neurofibromatosis types 1 and 2. J Neurosurg (1991) 1.25
Regulation of human ornithine decarboxylase expression by the c-Myc.Max protein complex. J Biol Chem (1993) 1.25
Polygenic inheritance of Tourette syndrome, stuttering, attention deficit hyperactivity, conduct, and oppositional defiant disorder: the additive and subtractive effect of the three dopaminergic genes--DRD2, D beta H, and DAT1. Am J Med Genet (1996) 1.24
Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene. New Biol (1991) 1.22
Treatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus 1. Cancer Res (1995) 1.22
A 10-amino-acid sequence in the N-terminal A/B domain of thyroid hormone receptor alpha is essential for transcriptional activation and interaction with the general transcription factor TFIIB. Mol Cell Biol (1995) 1.21
First observation of CP violation in the decays of B(s)0 mesons. Phys Rev Lett (2013) 1.21
Synthesis of the mannosyl-O-serine (threonine) linkage of glycoproteins from polyisoprenylphosphate mannose in yeast (Hansenula holstii). Arch Biochem Biophys (1975) 1.20
Quantitative assay by flow cytometry of the mitochondrial membrane potential in intact cells. Biochim Biophys Acta (1998) 1.19
Constitutive activation of STAT3 and STAT5 is present in the majority of nasopharyngeal carcinoma and correlates with better prognosis. Br J Cancer (2003) 1.19
A perspective on medical infrared imaging. J Med Eng Technol (2005) 1.17
Identification of a third metalloprotease toxin gene in extraintestinal isolates of Bacteroides fragilis. Infect Immun (1999) 1.17
Studies of the 48 bp repeat polymorphism of the DRD4 gene in impulsive, compulsive, addictive behaviors: Tourette syndrome, ADHD, pathological gambling, and substance abuse. Am J Med Genet (1999) 1.17
Effect of ionizing radiation on the human brain: white matter and gray matter T1 in pediatric brain tumor patients treated with conformal radiation therapy. Int J Radiat Oncol Biol Phys (2001) 1.17
The femR315 gene from Staphylococcus aureus, the interruption of which results in reduced methicillin resistance, encodes a phosphoglucosamine mutase. J Bacteriol (1997) 1.16
Waist circumference, body mass index and waist to hip ratio for prediction of the metabolic syndrome in Chinese. Nutr Metab Cardiovasc Dis (2009) 1.16
CYP2J subfamily cytochrome P450s in the gastrointestinal tract: expression, localization, and potential functional significance. Mol Pharmacol (1997) 1.15
Structure, function, and molecular modeling approaches to the study of the intestinal dipeptide transporter PepT1. J Pharm Sci (1998) 1.15
Retroposition in a family of carcinoma-associated antigen genes. Mol Cell Biol (1993) 1.15
Detection of cytomegalovirus reactivation in cancer patients receiving chemotherapy. Clin Microbiol Infect (2007) 1.14
Distribution of 16S rRNA methylases among different species of Gram-negative bacilli with high-level resistance to aminoglycosides. Eur J Clin Microbiol Infect Dis (2010) 1.14
Biochemical characterization of the human liver cytochrome P450 arachidonic acid epoxygenase pathway. Arch Biochem Biophys (1996) 1.14
Molecular cloning and characterization of a rabbit eIF2C protein. Gene (1998) 1.14